315 related articles for article (PubMed ID: 30317622)
1. Oleuropein inhibits migration ability through suppression of epithelial-mesenchymal transition and synergistically enhances doxorubicin-mediated apoptosis in MCF-7 cells.
Choupani J; Alivand MR; M Derakhshan S; Zaeifizadeh M; S Khaniani M
J Cell Physiol; 2019 Jun; 234(6):9093-9104. PubMed ID: 30317622
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol promotes sensitization to Doxorubicin by inhibiting epithelial-mesenchymal transition and modulating SIRT1/β-catenin signaling pathway in breast cancer.
Jin X; Wei Y; Liu Y; Lu X; Ding F; Wang J; Yang S
Cancer Med; 2019 Mar; 8(3):1246-1257. PubMed ID: 30697969
[TBL] [Abstract][Full Text] [Related]
3. Molecular iodine impairs chemoresistance mechanisms, enhances doxorubicin retention and induces downregulation of the CD44+/CD24+ and E-cadherin+/vimentin+ subpopulations in MCF-7 cells resistant to low doses of doxorubicin.
Bontempo A; Ugalde-Villanueva B; Delgado-González E; Rodríguez ÁL; Aceves C
Oncol Rep; 2017 Nov; 38(5):2867-2876. PubMed ID: 28901484
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer.
Xu J; Liu D; Niu H; Zhu G; Xu Y; Ye D; Li J; Zhang Q
J Exp Clin Cancer Res; 2017 Jan; 36(1):19. PubMed ID: 28126034
[TBL] [Abstract][Full Text] [Related]
5. The inhibitory effects of deep-sea water on doxorubicin‑induced epithelial-mesenchymal transition.
Chun SY; Kim S; Nam KS
Oncol Rep; 2017 Aug; 38(2):1163-1171. PubMed ID: 28627650
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1.
Cha BK; Kim YS; Hwang KE; Cho KH; Oh SH; Kim BR; Jun HY; Yoon KH; Jeong ET; Kim HR
Oncotarget; 2016 Aug; 7(35):57213-57227. PubMed ID: 27528025
[TBL] [Abstract][Full Text] [Related]
7. Lutein inhibits proliferation, invasion and migration of hypoxic breast cancer cells via downregulation of HES1.
Li Y; Zhang Y; Liu X; Wang M; Wang P; Yang J; Zhang S
Int J Oncol; 2018 Jun; 52(6):2119-2129. PubMed ID: 29620169
[TBL] [Abstract][Full Text] [Related]
8. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
9. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway.
Chen JM; Bai JY; Yang KX
IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742
[TBL] [Abstract][Full Text] [Related]
10. miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4.
Du F; Yu L; Wu Y; Wang S; Yao J; Zheng X; Xie S; Zhang S; Lu X; Liu Y; Chen W
Cell Death Dis; 2019 Dec; 10(12):922. PubMed ID: 31801953
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Cytotoxicity of Renieramycin M and Doxorubicin in MCF-7 Breast Cancer Cells.
Tun JO; Salvador-Reyes LA; Velarde MC; Saito N; Suwanborirux K; Concepcion GP
Mar Drugs; 2019 Sep; 17(9):. PubMed ID: 31527453
[TBL] [Abstract][Full Text] [Related]
12. Thymoquinone inhibits cancer metastasis by downregulating TWIST1 expression to reduce epithelial to mesenchymal transition.
Khan MA; Tania M; Wei C; Mei Z; Fu S; Cheng J; Xu J; Fu J
Oncotarget; 2015 Aug; 6(23):19580-91. PubMed ID: 26023736
[TBL] [Abstract][Full Text] [Related]
13. 3,5,4'-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
Tsai JH; Hsu LS; Lin CL; Hong HM; Pan MH; Way TD; Chen WJ
Toxicol Appl Pharmacol; 2013 Nov; 272(3):746-56. PubMed ID: 23921149
[TBL] [Abstract][Full Text] [Related]
14. Synergistic breast cancer suppression efficacy of doxorubicin by combination with glycyrrhetinic acid as an angiogenesis inhibitor.
Shi J; Li J; Li J; Li R; Wu X; Gao F; Zou L; Mak WWS; Fu C; Zhang J; Leung GP
Phytomedicine; 2021 Jan; 81():153408. PubMed ID: 33234363
[TBL] [Abstract][Full Text] [Related]
15. Camel Urine Promotes Sensitization to Doxorubicin by Inhibiting Epithelial-Mesenchymal Transition and Modulating NF-κB-Snail Signaling Pathway in Breast Cancer Cells.
Al-Mutairi MS; Matar IK; Alfadli S; Al-Mutairi A
Asian Pac J Cancer Prev; 2021 Dec; 22(12):4017-4029. PubMed ID: 34967584
[TBL] [Abstract][Full Text] [Related]
16. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation.
Zhang ZL; Jiang QC; Wang SR
Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822
[TBL] [Abstract][Full Text] [Related]
17. NFκBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
Velaei K; Samadi N; Soltani S; Barazvan B; Soleimani Rad J
Breast Cancer; 2017 Jul; 24(4):552-561. PubMed ID: 27878697
[TBL] [Abstract][Full Text] [Related]
18. The Effect of TIGAR Knockdown on Apoptotic and Epithelial-Mesenchymal Markers Expression in Doxorubicin-Resistant Non-Small Cell Lung Cancer A549 Cell Lines.
Agca CA; Kırıcı M; Nedzvetsky VS; Gundogdu R; Tykhomyrov AA
Chem Biodivers; 2020 Sep; 17(9):e2000441. PubMed ID: 32639659
[TBL] [Abstract][Full Text] [Related]
19. A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance.
Tsou SH; Chen TM; Hsiao HT; Chen YH
PLoS One; 2015; 10(1):e0116747. PubMed ID: 25635866
[TBL] [Abstract][Full Text] [Related]
20. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1.
Yang X; Hu Q; Hu LX; Lin XR; Liu JQ; Lin X; Dinglin XX; Zeng JY; Hu H; Luo ML; Yao HR
Discov Med; 2017 Sep; 24(131):75-85. PubMed ID: 28972876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]